Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention

摘要: Platelets play a central role in the pathophysiology of atherothrombosis, an inappropriate platelet activation leading to acute ischemic complications (acute myocardial infarction, stroke). In view this, platelets are major target for pharmacotherapy. Presently, main classes antiplatelet agents approved use such aspirin and fhienopyridines. Although treatment with these two types drugs, alone or combination, leads significant reduction non-fatal infarction (−32%), stroke (−25%), cardiovascular death (−17%), residual risk persists. Newer have addressed some, but not all, limitations. Vis-a-vis their net clinical benefit, higher potency some them is associated rise bleeding complications. Moreover, newer fhienopyridines do show advantages over above older ones as stroke. A concerted effort that takes into consideration clinical, genetic, laboratory information increasingly recognized direction be pursued area. The well-established road signs epidemiology will provide define potentially useful targets pharmacology.